233 related articles for article (PubMed ID: 24085786)
1. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
2. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
3. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
[TBL] [Abstract][Full Text] [Related]
4. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
5. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
6. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
[TBL] [Abstract][Full Text] [Related]
7. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
8. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
[TBL] [Abstract][Full Text] [Related]
9. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
Li P; Lin JE; Schulz S; Pitari GM; Waldman SA
Curr Mol Pharmacol; 2009 Nov; 2(3):285-92. PubMed ID: 20021465
[TBL] [Abstract][Full Text] [Related]
10. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
11. Silencing the intestinal GUCY2C tumor suppressor axis requires
Pattison AM; Barton JR; Entezari AA; Zalewski A; Rappaport JA; Snook AE; Waldman SA
Cancer Biol Ther; 2020 Sep; 21(9):799-805. PubMed ID: 32594830
[TBL] [Abstract][Full Text] [Related]
12. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
13. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
14. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity.
Lin JE; Snook AE; Li P; Stoecker BA; Kim GW; Magee MS; Garcia AV; Valentino MA; Hyslop T; Schulz S; Waldman SA
PLoS One; 2012; 7(2):e31686. PubMed ID: 22384056
[TBL] [Abstract][Full Text] [Related]
15. Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Li P; Waldman SA
Cancer Biol Ther; 2010 Aug; 10(3):211-8. PubMed ID: 20592492
[TBL] [Abstract][Full Text] [Related]
16. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
17. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine.
Li P; Lin JE; Chervoneva I; Schulz S; Waldman SA; Pitari GM
Am J Pathol; 2007 Dec; 171(6):1847-58. PubMed ID: 17974601
[TBL] [Abstract][Full Text] [Related]
18. Sex modulates intestinal transformation by the tumor-suppressor GCC.
Li P; Schulz S; Pitari GM; Waldman SA
Clin Transl Sci; 2008 Sep; 1(2):146-50. PubMed ID: 20443837
[TBL] [Abstract][Full Text] [Related]
19. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.
Rappaport JA; Entezari AA; Caspi A; Caksa S; Jhaveri AV; Stanek TJ; Ertel A; Kupper J; Fortina PM; McMahon SB; Jaynes JB; Snook AE; Waldman SA
Cell Mol Gastroenterol Hepatol; 2022; 13(4):1276-1296. PubMed ID: 34954189
[TBL] [Abstract][Full Text] [Related]
20. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
